CNSP
Income statement / Annual
Last year (2023), CNS Pharmaceuticals, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, CNS Pharmaceuticals, Inc.'s net income was -$18.85 M.
See CNS Pharmaceuticals, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
| Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$4,134.00 |
$11,756.00 |
$13,070.00 |
$11,096.00 |
$1,955.00 |
$0.00 |
$0.00 |
| Gross Profit |
-$4,134.00 |
-$11,756.00 |
-$13,070.00 |
-$11,096.00 |
-$1,955.00 |
$0.00 |
$0.00 |
| Gross Profit Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$14.10 M
|
$9.30 M
|
$9.35 M
|
$5.06 M
|
$1.85 M
|
$21,267.00
|
$32,638.00
|
| General & Administrative
Expenses |
$4.77 M
|
$5.97 M
|
$4.68 M
|
$4.39 M
|
$1.98 M
|
$860,520.00
|
$437,921.00
|
| Selling & Marketing
Expenses |
-$4,134.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$255,454.00
|
| Selling, General &
Administrative Expenses |
$4.77 M
|
$5.97 M
|
$4.68 M
|
$4.39 M
|
$1.98 M
|
$860,520.00
|
$182,467.00
|
| Other Expenses |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
-$6.46 M |
$0.00 |
| Operating Expenses |
$18.87 M |
$15.27 M |
$14.03 M |
$9.45 M |
$3.83 M |
$881,787.00 |
$215,105.00 |
| Cost And Expenses |
$18.87 M |
$15.27 M |
$14.03 M |
$9.45 M |
$3.83 M |
$881,787.00 |
$215,105.00 |
| Interest Income |
$27,687.00 |
$7.03 |
$9.29 |
$3.26 |
$44.23 |
$0.00 |
$10,217.00 |
| Interest Expense |
-$13,805.00 |
$7,027.00 |
$9,285.00 |
$3,264.00 |
$44,234.00 |
$46,697.00 |
$0.00 |
| Depreciation &
Amortization |
$4,134.00
|
$11,756.00
|
$13,070.00
|
$11,096.00
|
$1,955.00
|
$881,787.00
|
$516,252.00
|
| EBITDA |
-$18.86 M
|
-$15.26 M
|
-$14.01 M
|
-$9.44 M
|
-$3.83 M
|
-$7.35 M
|
-$215,100.00
|
| EBITDA Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
$13,882.00
|
-$7,027.00
|
-$9,285.00
|
-$3,264.00
|
-$44,234.00
|
-$6.46 M
|
-$4,262.00
|
| Income Before Tax |
-$18.85 M |
-$15.27 M |
-$14.04 M |
-$9.46 M |
-$3.88 M |
-$7.39 M |
-$219,362.00 |
| Income Before Tax Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
-$4.00 |
$7,027.00 |
$9,285.00 |
$3,264.00 |
$42,279.00 |
$46,697.00 |
-$516,252.00 |
| Net Income |
-$18.85 M |
-$15.27 M |
-$14.50 M |
-$9.46 M |
-$3.88 M |
-$7.39 M |
-$526,469.00 |
| Net Income Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| EPS |
-251.35 |
-560.83 |
-852.66 |
-859.81 |
-7.15 |
-16.83 |
-20 |
| EPS Diluted |
-250.19 |
-560.83 |
-825.04 |
-853.68 |
-7.15 |
-16.83 |
-20 |
| Weighted Average Shares
Out |
$75,000.00
|
$27,235.00
|
$17,000.00
|
$11,000.00
|
$0.00
|
$0.00
|
$0.00
|
| Weighted Average Shares
Out Diluted |
$75,347.00
|
$27,235.00
|
$17,569.00
|
$11,079.00
|
$0.00
|
$0.00
|
$0.00
|
| Link |
|
|
|
|
|
|
|
